Bibliometric and visualization analysis of HER2-low expression in breast cancer from 2000 to 2024

OBJECTIVE: This bibliometric study analyzed research articles published between 2000 and 2024, identified influential publications, key contributing authors and journals, and depicted the developmental trajectory of HER2-low breast cancer research. METHODS: Publications on HER2-low expression in breast cancer from 2000 to 2024 were retrieved from the Web of Science Core Collection (WoSCC) database. Bibliometric analysis and data visualization were performed using VOSviewer, CiteSpace, and R 4.3.3. RESULTS: The analysis covered a total of 592 articles, showing a sharp rise in publication output after 2021. China, the United States, France, Japan, and Italy were identified as the top 5 countries contributing research on HER2-low expression in breast cancer. The 5 leading institutions in this field were Unicancer, University of Texas System, Harvard University, UTMD Anderson Cancer Center, and Fudan University. The most prolific journals publishing studies on HER2-low expression in breast cancer included Breast Cancer Research and Treatment, Cancers, Frontiers in Oncology, Clinical Cancer Research, and Breast Cancer Research. The most productive authors were Giuseppe Curigliano and Xu Binghe. Emerging research topics included advancements in the treatment of HER2-low expression, as well as the development of detection methods and guidelines. CONCLUSION: This study provides an overview of articles on HER2-low expression in breast cancer published over the past 24 years. It highlights the most frequently cited papers, authors, and journals, identifying emerging trends in the field. These findings reflect the continuous evolution of HER2 as a therapeutic target in breast cancer treatment.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051513
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bibliometric and visualization analysis of HER2-low expression in breast cancer from 2000 to 2024

Yunhe Gao, Min Yao, Yifeng Li, Bo Ren
4 links
Medicine
HER2/EGFR in Cancer Research
article

Bibliometric and visualization analysis of HER2-low expression in breast cancer from 2000 to 2024

Yunhe Gao, Min Yao, Yifeng Li, Bo Ren
article en

Abstract

OBJECTIVE: This bibliometric study analyzed research articles published between 2000 and 2024, identified influential publications, key contributing authors and journals, and depicted the developmental trajectory of HER2-low breast cancer research. METHODS: Publications on HER2-low expression in breast cancer from 2000 to 2024 were retrieved from the Web of Science Core Collection (WoSCC) database. Bibliometric analysis and data visualization were performed using VOSviewer, CiteSpace, and R 4.3.3. RESULTS: The analysis covered a total of 592 articles, showing a sharp rise in publication output after 2021. China, the United States, France, Japan, and Italy were identified as the top 5 countries contributing research on HER2-low expression in breast cancer. The 5 leading institutions in this field were Unicancer, University of Texas System, Harvard University, UTMD Anderson Cancer Center, and Fudan University. The most prolific journals publishing studies on HER2-low expression in breast cancer included Breast Cancer Research and Treatment, Cancers, Frontiers in Oncology, Clinical Cancer Research, and Breast Cancer Research. The most productive authors were Giuseppe Curigliano and Xu Binghe. Emerging research topics included advancements in the treatment of HER2-low expression, as well as the development of detection methods and guidelines. CONCLUSION: This study provides an overview of articles on HER2-low expression in breast cancer published over the past 24 years. It highlights the most frequently cited papers, authors, and journals, identifying emerging trends in the field. These findings reflect the continuous evolution of HER2 as a therapeutic target in breast cancer treatment.

MedicineVol. 105(46)
Jilin University (CN), Second Affiliated Hospital of Jilin University (CN)
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon